US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
US5576311A
(en)
*
|
1994-11-30 |
1996-11-19 |
Pharmos Corporation |
Cyclodextrins as suspending agents for pharmaceutical suspensions
|
US5976573A
(en)
*
|
1996-07-03 |
1999-11-02 |
Rorer Pharmaceutical Products Inc. |
Aqueous-based pharmaceutical composition
|
US5800832A
(en)
*
|
1996-10-18 |
1998-09-01 |
Virotex Corporation |
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
|
US5955097A
(en)
*
|
1996-10-18 |
1999-09-21 |
Virotex Corporation |
Pharmaceutical preparation applicable to mucosal surfaces and body tissues
|
TW503113B
(en)
*
|
1997-01-16 |
2002-09-21 |
Senju Pharma Co |
Aqueous suspension for nasal administration
|
KR100508227B1
(ko)
*
|
1997-03-14 |
2006-03-23 |
센주 세이야꾸 가부시키가이샤 |
로테프레드놀에타보네이트수성현탁액
|
US20050048102A1
(en)
*
|
1997-10-16 |
2005-03-03 |
Virotex Corporation |
Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
|
SE9704186D0
(sv)
*
|
1997-11-14 |
1997-11-14 |
Astra Ab |
New composition of matter
|
KR100683510B1
(ko)
*
|
1998-01-22 |
2007-02-16 |
산텐 세이야꾸 가부시키가이샤 |
플루오로메톨론 현탁형 점안제
|
US6103266A
(en)
*
|
1998-04-22 |
2000-08-15 |
Tapolsky; Gilles H. |
Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
|
EP1109581A1
(de)
*
|
1998-09-02 |
2001-06-27 |
Allergan Sales, Inc. |
Geschützte cyclodextrin-enthaltende zusammensetzungen
|
US6395746B1
(en)
|
1998-09-30 |
2002-05-28 |
Alcon Manufacturing, Ltd. |
Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
|
US6509327B1
(en)
|
1998-09-30 |
2003-01-21 |
Alcon Manufacturing, Ltd. |
Compositions and methods for treating otic, ophthalmic and nasal infections
|
US6716830B2
(en)
|
1998-09-30 |
2004-04-06 |
Alcon, Inc. |
Ophthalmic antibiotic compositions containing moxifloxacin
|
ES2188563T3
(es)
*
|
1999-06-22 |
2003-07-01 |
Boehringer Ingelheim Int |
Solucion estable de xilometazolina y oximetazolina.
|
FR2796553B1
(fr)
*
|
1999-07-22 |
2001-09-28 |
Warner Lambert Co |
Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
|
TR200200737T2
(tr)
|
1999-09-24 |
2002-08-21 |
Alcon, Inc. |
Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
|
AR026073A1
(es)
|
1999-10-20 |
2002-12-26 |
Nycomed Gmbh |
Composicion farmaceutica acuosa que contiene ciclesonida
|
CA2356177A1
(en)
*
|
1999-10-20 |
2001-04-26 |
Kazuya Takanashi |
Aqueous pharmaceutical compositions
|
TR200201322T2
(tr)
*
|
1999-11-18 |
2002-11-21 |
Alcon, Inc. |
H1 antagonistleri ve güvenli bir steroid'in göz sağlık koşullarının tedavisi için kullanımı
|
US20040097486A1
(en)
*
|
1999-11-18 |
2004-05-20 |
Yanni John M. |
Use of an H1 antagonist and a safe steroid to treat eye conditions
|
AU2001262228A1
(en)
*
|
2000-05-15 |
2001-11-26 |
Pharmacia Italia S.P.A. |
Stabilized steroidal suspension
|
US6495534B2
(en)
*
|
2000-05-15 |
2002-12-17 |
Pharmacia & Upjohn Spa |
Stabilized aqueous suspensions for parenteral use
|
US6462033B2
(en)
|
2000-07-26 |
2002-10-08 |
Alcon Universal Ltd. |
Process for manufacturing compositions containing ciprofloxacin and hydrocortisone
|
BR0115415A
(pt)
*
|
2000-11-15 |
2003-09-09 |
Mohan A Chandavarkar |
Droga de combinação
|
EP1341541A4
(de)
*
|
2000-11-16 |
2004-11-17 |
Alcon Mfg Ltd |
Kombinationstherapie zur senkung und kontrolle des augeninnendrucks
|
BR0212898A
(pt)
*
|
2001-09-21 |
2004-10-13 |
Alcon Inc |
Método de tratamento de infecções do ouvido médio
|
US7001615B1
(en)
|
2001-12-07 |
2006-02-21 |
Alcon, Inc. |
Sustained release ophthalmic, otic and nasal suspension
|
US20090215735A1
(en)
*
|
2002-02-25 |
2009-08-27 |
Alcon, Inc. |
Topical solution formulations containing a corticosteroid and a cyclodextrin
|
AU2003280960A1
(en)
*
|
2002-07-15 |
2004-02-02 |
Alcon, Inc. |
Pharmaceutical compositions for otic use
|
ATE407662T1
(de)
*
|
2002-10-18 |
2008-09-15 |
Joel S Echols |
Dreischichtige tränenformulierung
|
AU2003301129A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Control Delivery Systems, Inc. |
Steroid compositions for intraocular use
|
DE122011100019I1
(de)
|
2003-01-21 |
2011-11-03 |
Senju Pharma Co |
Wassrige flussige zubereitung mit 2-amino-3-(4-bromobenzoyl) phenylessigsaure.
|
US20050069590A1
(en)
*
|
2003-09-30 |
2005-03-31 |
Buehler Gail K. |
Stable suspensions for medicinal dosages
|
US20050197303A1
(en)
*
|
2003-10-31 |
2005-09-08 |
Bausch & Lomb Incorporated |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
US20050095205A1
(en)
*
|
2003-10-31 |
2005-05-05 |
Ramesh Krishnamoorthy |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
AU2004285592B2
(en)
*
|
2003-11-03 |
2010-02-18 |
Norton Healthcare, Ltd. |
Soft steroid compositions for use in dry powder inhalers
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050250737A1
(en)
*
|
2003-11-12 |
2005-11-10 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
WO2005053708A1
(ja)
*
|
2003-12-02 |
2005-06-16 |
Senju Pharmaceutical Co., Ltd. |
ロテプレドノールエタボネート水性懸濁液剤
|
PE20050941A1
(es)
|
2003-12-16 |
2005-11-08 |
Nycomed Gmbh |
Suspensiones acuosas de ciclesonida para nebulizacion
|
DE602005011928D1
(de)
*
|
2004-01-20 |
2009-02-05 |
Allergan Inc |
Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
|
WO2005072710A2
(en)
*
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
US20050182039A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Bausch & Lomb Incorporated |
Use of Loteprednol etabonate for the treatment of dry eye
|
BRPI0509220A
(pt)
|
2004-03-25 |
2007-09-04 |
Bausch & Lomb |
método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
BRPI0513243B8
(pt)
*
|
2004-07-12 |
2021-05-25 |
Allergan Inc |
composições oftálmicas e respectivos usos
|
WO2006031848A2
(en)
*
|
2004-09-15 |
2006-03-23 |
Ivax Corporation |
Corticosteroid topical dispersion with low content of surfactant
|
JP4968955B2
(ja)
*
|
2005-05-10 |
2012-07-04 |
アルコン,インコーポレイテッド |
眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用
|
PL1885336T3
(pl)
*
|
2005-05-10 |
2009-08-31 |
Alcon Inc |
Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
|
CN101272807A
(zh)
*
|
2005-09-26 |
2008-09-24 |
皮埃蒙特医药品有限公司 |
使用非离子表面活性剂促进跨膜药物输送到中耳治疗和预防中耳炎的方法
|
EA200800949A1
(ru)
*
|
2005-09-26 |
2008-08-29 |
ПЬЕДМОН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи |
Способы лечения и профилактики среднего отита посредством химических веществ, способствующих проникновению, для обеспечения трансмембранного поступления лекарственного средства в среднее ухо
|
US20090082321A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Allergan, Inc. |
Steroid containing drug delivery systems
|
MX2007012061A
(es)
|
2005-10-18 |
2007-12-13 |
Allergan Inc |
Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
|
US20070093461A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Bausch & Lomb Incorporated |
Effect of Loteprednol etabonate on vascular dysfunction
|
US20070110812A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Bausch & Lomb Incorporated |
Ophthalmic composition for dry eye therapy
|
US20070128251A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Piedmont Pharmaceuticals, Inc. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
US7955632B2
(en)
|
2005-12-07 |
2011-06-07 |
Bayer B.V. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
BRPI0709410A2
(pt)
*
|
2006-03-20 |
2011-07-12 |
Javelin Pharmaceuticals Inc |
composição farmacêutica e método para tratar um mamìfero necessitando de um agente analgésico, anti-inflamatório ou um antipirético
|
AU2007230716B2
(en)
|
2006-03-28 |
2012-05-03 |
Javelin Pharmaceuticals, Inc. |
Formulations of low dose diclofenac and beta-cyclodextrin
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
WO2008002118A1
(es)
*
|
2006-06-27 |
2008-01-03 |
Arturo Jimenez Bayardo |
Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
|
CN103550136B
(zh)
|
2006-07-21 |
2016-04-13 |
生物递送科学国际公司 |
吸收增强的经粘膜递送装置
|
WO2008027340A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
WO2008027341A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
WO2008030557A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Johns Hopkins University |
Compositions and methods for enhancing transport through mucus
|
TWI415629B
(zh)
|
2006-10-26 |
2013-11-21 |
Otsuka Pharma Co Ltd |
含有瑞巴匹特之水性醫藥懸浮物及其製造方法
|
WO2008057364A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Riolan Technologies, Inc. |
Method for treating blepharitis
|
US20080119448A1
(en)
*
|
2006-11-02 |
2008-05-22 |
Friedlaender Mitchell H |
Methods of treating an ocular allergy with low dose dexamethasone
|
CN101721714B
(zh)
*
|
2009-12-18 |
2011-12-07 |
重庆莱美药业股份有限公司 |
实体瘤被动靶向性抗癌前药及其制备方法
|
US8889193B2
(en)
|
2010-02-25 |
2014-11-18 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
WO2012039979A2
(en)
|
2010-09-10 |
2012-03-29 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
MX2013012308A
(es)
*
|
2011-04-22 |
2014-01-31 |
Alcon Res Ltd |
Composicion oftalmica con un sistema de mejoramiento de viscosidad de dos agentes mejoradores de viscosidad diferentes.
|
EP2744572B1
(de)
|
2011-08-18 |
2017-12-13 |
BioDelivery Sciences International, Inc. |
Missbrauchsichere mukoadhäsive vorrichtungen zur verabreichung von buprenorphin
|
CA2851492A1
(en)
|
2011-09-22 |
2013-03-28 |
Bausch & Lomb Incorporated |
Ophthalmic gel compositions
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
JP5883539B2
(ja)
|
2012-03-16 |
2016-03-15 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
Hif−1阻害剤の送達のための放出制御製剤
|
EA030318B1
(ru)
|
2012-03-16 |
2018-07-31 |
Дзе Джонс Хопкинс Юниверсити |
Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
|
CA2871745C
(en)
|
2012-05-03 |
2023-01-24 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
NZ700875A
(en)
*
|
2012-05-03 |
2017-03-31 |
Kala Pharmaceuticals Inc |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
KR102140989B1
(ko)
|
2012-05-03 |
2020-08-04 |
칼라 파마슈티컬스, 인크. |
개선된 점막 수송을 나타내는 제약 나노입자
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
AU2013256008B2
(en)
|
2012-05-04 |
2016-02-25 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
CN103565742A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
氟米龙滴眼液
|
CN103565740A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
依碳氯替泼诺混悬滴眼液
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
JP6669499B2
(ja)
|
2013-02-15 |
2020-03-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物
|
JP2016510000A
(ja)
|
2013-02-20 |
2016-04-04 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物およびその使用
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
US20150164882A1
(en)
|
2013-07-22 |
2015-06-18 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
|
US20160279055A1
(en)
|
2013-07-22 |
2016-09-29 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
|
KR20160099084A
(ko)
|
2013-11-01 |
2016-08-19 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정질 형태 및 그의 용도
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
DK3216451T3
(da)
*
|
2014-11-07 |
2022-05-23 |
Santen Pharmaceutical Co Ltd |
Oftalmisk vandig sammensætning
|
US10485757B2
(en)
|
2015-01-27 |
2019-11-26 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
CN106279325A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
CN106279324A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
CN106892953A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
CN106892952A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
AU2017324251A1
(en)
|
2016-09-08 |
2019-03-21 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CA3036340A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|